According to an abstract released on November 13th, Calithera’s (NASDAQ:CALA) Triple-Negative-Breast-Cancer appears to show a very positive signal, especially among African-American Women. However, traders and investors seem to be misinterpret the company’s recent combo data with Bristol-Myers Squibb.
Story Continues
